PharmEasy is closing in on $120 million in equity round
The transaction, which is expected to close by the end of the month, will value the five-yearold company at $500-600 million, according to multiple sources aware of the development.
The transaction, which is expected to close by the end of the month, will value the five-year old company at $500-600 million, according to multiple sources aware of the development. Other new investors entering the investor cap table include venture capital firm Aspada and a Korean investment firm.
The round, once it closes, will be one of the largest in the country’s online pharma space, a sector that continues to face a combination of lack of regulatory clarity and conflicting court orders, but has also seen all the major players in the segment either scoop up or go to market for raising substantial capital.
PharmEasy and LGT declined to comment. CDPQ has also declined to comment on the PharmEasy deal.
As per the terms of the deal, the investment will be made in 91streets Media Technologies, the parent company of PharmEasy, and comes a little more than three months after the online drugs retailer started the merger process with pharmaceutical distribution company Ascent Health and Wellness.
ET reported the news of the merger in its March 28 edition. Prior to merger, the promoters of Ascent Health and Wellness held a substantial chunk in PharmEasy.
Once the merger is through, 91street Media will emerge as the holding company of both PharmEasy and Ascent Health and Wellness, which allows it to not only control front-facing online pharma sales and logistics, but also its critical distribution and supply chain channels.
Ascent, which caters to more than 25,000 retailers across the country, also works with a number of the top pharmaceutical companies, such as Zydus Cadila, Cipla and Sun Pharmaceuticals, along with notable hospital chains including Mumbai’s Nanavati Hospital and Manipal Hospitals.
The company provides the pharma majors with all channels of distribution, including retail and institutional, while separately managing the pharmaceutical supplies, and acting as a vendor for the hospital chains.
For the country’s online drug retailers, gaining control over distribution and supply chain is critical. Almost all of them have invested in pharmaceutical distributors, but have thus far kept the investments at arm’s length.
Additionally, talks with Soft-Bank — first reported by business daily Mint — are continuing, the sources cited above added.
The latest round of funding comes about 10 months after the Mumbai-based PharmEasy scored $50 million in fresh capital in a round led by Eight Roads Ventures, the proprietary investment arm of Fidelity International; F Prime Capital, the US-based sister fund of Eight Roads Ventures; Nandan Nilekani-backed investment firm Fundamentum and San Francisco-based hedge Fund Think Advisors. It had valued the firm at $150 million at the time.
CDPQ - Caisse de dépôt et placement du Québec - which manages assets of more than $309.5 billion, has largely focused on betting on core sectors such as automobiles, infrastructure, real estate, stressed assets and renewable energy. It is, however, an investor in Fundamentum.
Separately, LGT, which has been reported to have assets under management of about $207.5 billion, recently took over WGC Wealth, the erstwhile wealth management arm of the debt-laden DHFL group, renaming it Validus Wealth.